X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: Margins under pressure - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Aug 4, 2003

    Cipla: Margins under pressure

    Domestic pharma major, Cipla announced its first quarter FY04 results recently. While the company has posted a 13% increase in the topline, a marginal drop in the operating efficiency has restricted the company's bottomline growth at 11%. Let us briefly evaluate the performance of the company during 1QFY04.

    (Rs m) 1QFY03 1QFY04 Change
    Net Sales 4,030 4,542 12.7%
    Other Income 48 67 39.7%
    Total expenditure 3,207 3,669 14.4%
    Operating Profit (EBDIT) 823 874 6.2%
    Operating Profit Margin (%) 20.4% 19.2%  
    Interest 2 10 330.4%
    Depreciation 70 88 25.0%
    Profit before Tax 798 843 5.6%
    Tax 192 171 -10.9%
    Profit after Tax/(Loss) 606 672 10.8%
    Net profit margin (%) 15.0% 14.8%  
    No. of Shares (m) 60.0 60.0  
    Earnings per share* 40.4 44.8  
    Current P/e ratio   18.0  
    *(annualised)      

    Cipla recorded a healthy growth in the net sales. However, a 25% rise in the raw material expense has affected the margins of the company. Raw material cost as a percentage of sales has gone up from 44% in 1QFY03 to 49% in the current quarter. This was primarily due to the change in the product mix of the company. Depreciation charges were also on the higher side on account of provision being made for the second phase of the Goa unit, which commenced commercial production during the quarter under review. Other income increased due to higher export benefits received during the current quarter. A drop in operating profit margins, sharp rise in the interest cost and a drop in the tax provisions on account of Sec 80I benefits have resulted in Cipla registering an 11% rise in net profits. Let us now study the revenue break up of the company.

    Revenue break-up
    (Rs m) 1QFY03 1QFY04 Change
    Domestic 2,624 3,054 16.4%
    Exports:      
    Formulations 507 884 74.3%
    Bulk drugs 882 562 -36.3%
    Other operating income 16 42 161.1%
    Total 4,030 4,542 12.7%

    A close examination of the revenues indicates that although the export of formulations saw a steep rise, bulk drugs exports registered a sharp decline. This was on account of postponement of purchases by customers due to delay in patent rulings. On the domestic front, Cipla managed to outperform the industry with strong performance in the anti-biotic, anti-asthmatics and anti-hypertensives segments. The company has launched ‘Tiotropium’, a dry powder inhaler in the anti-asthma segment during the current quarter. Exports of formulations have seen a 74% growth. The growth was fuelled by good performance in the anti-AIDS segment.

    Cipla has indicated that the export of CFC - free inhalers to Europe will commence as soon as the required regulatory approvals are received. However, the company has refused to give a time frame within which it expects to receive the requisite approval.

    At Rs 807, Cipla is trading at a P/E of 18x its 1QFY04 earnings. Given the company’s ability to outperform in the domestic markets and the likely approval for export of CFC - free inhalers, the prospects of the company seem bright. However, delay in regulatory approval for products for which Cipla is the bulk drugs supplier and the uncertainty in respect of DPCO remain a cause for concern.

     

     

    Equitymaster requests your view! Post a comment on "Cipla: Margins under pressure". Click here!

      
     

    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CIPLA SHARE PRICE


    Aug 22, 2017 03:36 PM

    TRACK CIPLA

    CIPLA 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE CIPLA WITH

    MARKET STATS